|
Course of the trial. |
||
| IFN gamma |
Placebo |
|
|
|
||
| Randomized patients |
18 |
14 |
| Treatment interruptions |
2 (11.1%) |
4 (28.6%) |
| Voluntary abandoners |
2 (11.1%) |
2 (14.3%) |
| Deaths |
0 |
2 (14.3%) |
| Completed 6 months of treatment |
16 (88.9%) |
10 (71.4%) |
| Follow-up withdrawals |
3 (16.7%) |
2 (14.3%) |
| Voluntary abandoners |
1 (5.5%) |
0 |
| Deaths |
2 (11.1%) |
2 (14.3%) |
| Completed 12 months of follow-up |
13 (72.2%) |
8 (57.1%) |
| Total deaths |
2 (11.1%) |
5* (35.7%) |
|
* One of the voluntary abandoners in this group died | ||
Milanés-Virelles et al. BMC Infectious Diseases 2008 8:17 doi:10.1186/1471-2334-8-17 |
||